AstraZeneca Seeks Cmte. Input On Further Iressa Marketing Steps
This article was originally published in The Pink Sheet Daily
Executive Summary
AstraZeneca publishing "Dear Doctor" letter on failed survival study results in oncology journals for foreseeable future. Efforts to inform physicians of trial results have led to a "substantial reduction" in new prescriptions for gefitinib, company says.